Targeting properdin - Structure and function of a novel family of tick-derived complement inhibitors

Katharina Braunger^{*,a}, Jiyeon Ahn^{*,a}, Matthijs M. Jore^{*,a,1}, Steven Johnson^{a,b}, Terence Tang^{a,2}, Dennis V. Pedersen^c, Gregers R. Andersen^c and Susan M. Lea^{a,b,d}

*These authors contributed equally

^a Sir William Dunn School of Pathology, University of Oxford, OX1 3RE Oxford, United Kingdom

^b Center for Structural Biology, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, United States of America

^c Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus, Denmark

^d Central Oxford Structural Molecular Imaging Centre, University of Oxford, OX1 3RE Oxford, United Kingdom

¹ present address: Radboud University Medical Centre, Center for Molecular Life Sciences, Nijmegen, Netherlands

² present address: MRC Laboratory of Molecular Biology, Cambridge, United Kingdom

Correspondence should be addressed to S.M.L. (susan.lea@nih.gov)

Abstract

Activation of the serum-resident complement system begins a cascade that leads to activation of membrane-resident complement receptors on immune cells, thus coordinating serum and cellular immune responses. Whilst many molecules act to control inappropriate activation, Properdin is the only known positive regulator of the human complement system. By stabilising the alternative pathway C3 convertase it promotes complement self-amplification and persistent activation boosting the magnitude of the serum complement response by all triggers.

We have identified a novel family of alternative pathway complement inhibitors, hereafter termed CirpA. Functional and structural characterisation reveals that CirpA family directly bind to properdin, inhibiting its ability to promote complement activation, and leading to potent inhibition of the complement response in a species specific manner.

For the first time this study provides a full functional and structural characterization of a properdin inhibitor, opening avenues for future therapeutic approaches.

Introduction

The complement system plays pivotal roles in immunity and cellular homeostasis^{1, 2, 3}. The tightly regulated proteolytic cascade can be activated through the Classical pathway (CP), Lectin pathway (LP) and Alternative pathway (AP), all of which ultimately lead to the formation of a surface-bound AP C3 convertase C3bBb. This then cleaves C3 into C3a and C3b, inducing a self-amplification loop, and leading to opsonisation with C3b and release of the anaphylatoxin C3a. Exceeding a certain density of surface bound C3b triggers a shift in substrate preference

towards C5⁴. The resulting production of the anaphylatoxin C5a, and the first component of the membrane attack complex (MAC) C5b, initiate the terminal steps of the cascade.

A plethora of host proteins are known to attenuate the response, as excessive, inappropriate, or prolonged complement activation can be highly detrimental to host tissue^{5, 6}. A striking example is constituted by the disproportionate immune response seen in many severe COVID-19 cases of the ongoing pandemic^{7, 8, 9, 10}. In contrast, only a single positive regulator has been identified in the complement system: Properdin, also known as factor P (FP)^{11, 12, 13}.

FP natively forms oligomers which promote assembly of the C3bB proconvertase and stabilise the AP C3 convertase, thereby extending its half-life 5- to 10-fold and inhibiting its degradation by factor I^{12, 14, 15}. Besides this, there is an ongoing controversy about FP's potential role as a pattern recognition molecule, in which it is suggested to bind directly to activating surfaces, thereby recruiting C3 and inducing complement activation^{16, 17}.

FP is a highly flexible protein consisting of an N-terminal TGFβ binding (TB)-domain followed by six thrombospondin type I repeats (TSR)-domains. The convertase binding region lies in a vertex formed between two FP molecules, interacting head-to-tail. High resolution structures of pseudo-monomeric FP in isolation and bound to the C-terminal domain of C3b, as well as a moderate resolution structure of a FP-bound AP C3 convertase, have greatly improved our understanding of FP multimerization and convertase stabilization^{18, 19, 20}.

FP inhibition leading to complement downregulation has the potential to ameliorate conditions caused by the overactivation of complement on host tissue in a way which is preferable over inhibition at other stages. By acting at the level of the AP C3 convertases, FP-inhibition leads to a reduction in both C3a and C5a, as well as reduced MAC formation. FP-inhibition may also preserve non-amplified complement activation via CP and LP, allowing for some level of continued clearance of apoptotic cells. Additionally, FP concentration in serum (5-25 µg/mL) is much lower than for example C3 (1.2 mg/mL) or C5 (75 µg/mL), such that a lower dose of an inhibitory agent might be sufficient to demonstrate therapeutic effects²¹.

Tick-saliva presents a vast source for pharmaco-active proteins, targeting a wide array of immune mechanisms²². Their therapeutic potential can be illustrated with the example of Nomacopan (Coversin, Akari therapeutics), a recombinant variant of the lipocalin family protein OmCI (*Ornithodoros moubata* Complement Inhibitor), which is currently under investigation in several clinical trials at various stages. Its mechanism of action is binary, with tight binding of C5 inhibiting the terminal pathway of complement^{23, 24}, and sequestration of the proinflammatory eicosanoid leukotriene B4 (LTB4) within an internal binding cavity²⁵ providing additional anti-inflammatory function.

In this study we identified a novel family of complement inhibitors from the hard tick *Rhipicephalus pulchellus*, hereafter termed CirpA (Complement inhibitor from *R. pulchellus* of the alternative pathway). CirpA1 is shown to target human properdin, leading to potent AP inhibition. Functional analysis of six CirpA homologs demonstrates a highly species dependent activity profile.

In addition, we present crystal structures of four CirpA homologs, revealing a conserved lipocalin fold, and the crystal structure of the properdin-CirpA1 complex.

Our work represents the first comprehensive functional and structural characterisation of a properdin inhibitor. The in-depth structural and functional analysis gives insights into the mechanism of properdin binding and reveals a remarkable variety in lipocalin inhibition mechanisms.

Results

Tick saliva protein CirpA1 targets human Properdin

Fractionation of *R. pulchellus* salivary gland extract (SGE) had previously led to identification of the CirpT family of complement inhibitors²⁶. Strikingly, the first chromatographic step indicated a distinct second population with inhibitory activity specific for the alternative pathway of complement activation (Extended Data fig 1a). Using an analogous procedure, we further purified and enriched fractions with inhibitory activity, demonstrated by reduced MAC deposition in a standard complement alternative pathway activation assay using human serum (Fig 1a, b; Extended Data Fig. 1a,b).

The proteins in the active fractions were analysed by electrospray ionization-MS/MS following trypsin digest. Analysis against two published cDNA databases^{26, 27} resulted in a list of nine proteins containing a predicted signal peptide (Extended Data Fig. 1c). The candidates were expressed recombinantly in *Drosophila melanogaster* S2 cells and the culture supernatants tested for complement inhibitory activity. Only one protein, subsequently termed CirpA1, was shown to specifically inhibit the alternative pathway of complement activation (Fig. 1c, Extended Data Fig. 1d). CirpA1 significantly inhibited the formation of both C3a and C5a via the alternative pathway (figure 1d, e) suggesting it acts at the point of C3 cleavage.

To pinpoint the target of CirpA1, we performed a pull-down assay from human serum utilizing immobilised CirpA1. Western Blot analysis resulted in a single positive hit: Properdin, also known as complement factor P (FP, Figure 1f). FP is the only known positive regulator of the human complement system. In the alternative pathway, FP binds to the C-terminal domain of C3b in the C3 convertase (C3 C345c), thereby increasing convertase half-life approximately ten-fold. To gain a better understanding how CirpA1 binding to FP leads to inhibition of the alternative pathway of complement activation we investigated how it interferes with FP function. We generated biotinylated C3b from purified C3 to couple it to streptavidin magnetic beads in a physiological orientation⁴. We incubated the C3b coupled beads in human serum, supplemented with EDTA and EGTA to block complement activity, in presence or absence of CirpA1. Subsequent western blot analysis clearly shows that CirpA1 abolishes FP-C3b binding. Furthermore, CirpA1 is able to act in a competitive manner, releasing pre-bound FP (Fig 1g).

Figure 1 Identification and functional characterisation of CirpA1 from *Rhipicephalus pulchellus* salivary glands. (a) Experimental procedure leading to the identification of CirpA1 (b) Fractionation of salivary gland extract hydrophobic interaction chromatography (top) used to identify fractions with inhibitory activity against the alternative pathway in a AP haemolysis assay (bottom). (c) Inhibition of complement pathways by CirpA1 measured in WIESLAB assays using human serum. CirpA1 specifically inhibited the alternative pathway. Values were normalised for no-serum samples (0% MAC formation) and no-additive samples (100% MAC formation). Error bars, s.e.m. ($n = 3$). Curve fitting was carried out in GraphPad Prism using a dose response inhibition (variable slope) model. AP $IC_{50} = 13$ nM. (d-e) C3a (d) and C5a (e) levels in supernatants of the alternative pathway Wieslab assay. CirpA1 inhibited C3a and C5a formation through the alternative pathway; -ve = Ra-HBP2; +ve = EDTA. All proteins were added at a final concentration of 1 μ M. Values were baseline-corrected for buffer-only samples. Error bars, s.d. ($n = 3$ Wieslab samples). ns (not significant); **** $P < 0.001$ by unpaired two-tailed t-test, with no-additive sample as the reference. (f) CirpA1 binds FP, anti-FP blot using CirpA1 coated beads from serum compared to +ve and -ve controls (g) Anti-FP Western Blot after serum incubation of C3b-coupled beads in presence or absence of CirpA1 shows CirpA1 is able to prevent binding to C3b (E1) and displace the majority of pre-bound FP (E2, FT2); -ve = no added serum; +ve = no inhibitor.

The CirpA family of inhibitors show species specificity

To identify potential biologically relevant homologs, the CirpA1 sequence was used to query the expressed sequence tag database (NCBI) as well as in-house *R. appendiculatus*²⁸ and *R. pulchellus* sialomes. This search revealed five homologs across different tick species (Fig 2a, Extended Data fig. 2b) with varying sequence identity (hereafter named CirpA2-A6, pairwise sequence identity to CirpA1 43%-82% over ~200 residues). To compare their activity all CirpA homologs were expressed in *D. melanogaster* S2 cells and assessed regarding their ability to inhibit alternative pathway complement mediated haemolysis via sera from multiple mammalian species.

We tested inhibitory activity against human, monkey, rat, and guinea pig serum (Fig. 2b). CirpA1 showed comparable activity in human and monkey sera ($IC_{50} = 1.41 \times 10^{-8}$ and 1.38×10^{-8} respectively) but only weak effects in rat serum and was inactive in guinea pig. Interestingly, for CirpA2, which shares 82% of amino acids with CirpA1 and only differs in the C-terminal 57 residues, the inhibitory potential is lost in human and strongly reduced in monkey. In contrast, CirpA6, the homolog with the lowest sequence identity to CirpA1 (43%), shows almost identical inhibition behaviour in human ($IC_{50} = 1.40 \times 10^{-8}$), considerable activity in monkey and weak inhibition in rat. The homologs CirpA3-5 were inactive in the species tested in this study (Fig 2b).

CirpA proteins display a conserved lipocalin fold

To understand the distinct inhibition profiles, we set out to determine the structure of the different CirpA homologs. To that end we overexpressed the proteins in *Escherichia coli* and purified them via refolding from inclusion bodies. Using this strategy, we were able to purify CirpA1, A3, A4 and A5 and determine their structure using X-ray crystallography to a resolution of 2.0 Å, 2.1 Å, 1.8 Å and 1.9 Å respectively. (Fig 2 c, d, Table 1).

The structure of CirpA1 was solved by molecular replacement using the tick-derived complement inhibitor OmCI (pdb-id: 3ZUI) as an initial search model. The refined model of CirpA1 was used to determine the structures of CirpA3-5. All CirpA structures share a lipocalin fold with a short N-terminal α -helix followed by an eight-stranded beta-barrel and a longer C-terminal α -helix. Overall, the structures appear very similar, with the biggest conformational differences in the tilt angle of the C-terminal helix H2 as well as variations in loops between beta strands 4 and 5 (L4-5) and between strands 7 and 8 (L7-8).

Figure 2 Characterisation of the CirpA protein family (a) Sequence alignment of CirpA family members. CirpA1 was purified from *R. pulchellus*, CirpA2 and CirpA3 are homologs from the *R. pulchellus* transcriptome (Reichhardt 2020), CirpA4: GenBank CD794868.1, CirpA5 was identified from the *R. appendiculatus* transcriptome (Jore 2016), CirpA6: GenBank CK182034.1; Grey: residues conserved in five or more, blue: residues unique to homologs with anti-complement AP activity in fig. 2b, red: residues unique to CirpA1, black dots: residues involved in the CirpA1- FPΔ2,3 interface in the complex structure in fig. 3e according to PISA analysis. (b) AP haemolysis assay with serum from *Homo sapiens* (human), *Macaca fascicularis* (monkey), *Rattus norvegicus* (rat) and *Cavia porcellus* (guinea pig). Values were normalised for no-serum samples (0% lysis) and no-additive samples (100% lysis). Error bars, s.e.m. (n = 3). Curve fitting was carried out in GraphPad Prism using a dose response inhibition (variable slope) model. (c) Crystal structure of CirpA1. (d) Overlay of crystal structures of CirpA1, CirpA3, CirpA4 and CirpA5. Regions of high conformational variability between homologs indicated by dashed ellipsoids.

CirpA binds Properdin at the TSR5-6 junction

We next aimed to get more detailed insights into the mechanism of function of CirpA1 to potentially understand differences in inhibitory potential between the homologs. We first investigated whether FP was still able to form multimers upon binding of CirpA1. Size exclusion analysis of purified FP in presence of CirpA1 resulted in clear shifts towards higher molecular weight for all FP populations with no noticeable changes in population ratio (fig 3a). Hence, we concluded that CirpA1 binds all multimeric forms of FP without affecting multimer distribution.

Next, we set out to determine the structure of the CirpA1-FP. We chose to work with a minimal FP construct that had previously been used to determine the crystal structure of pseudo-monomeric, minimal functional unit of FP (hereafter referred to as FP Δ 2,3)^{18, 19}. It consists of a head-fragment with the TB domain as well as TSR1 and a tail fragment of TSR 4-6. Co-expression of both fragments in HEK293F cells results in formation of a vertex mimicking FP's physiological multimerization behaviour and is able to bind the C3 convertase¹⁸. Addition of CirpA1 to purified FP Δ 2,3 results in a distinct shift of molecular weight (fig 3b), as measured by SEC-MALS, indicating formation of a complex at 1:1 stoichiometry.

We were able to obtain crystals from the FP Δ 2,3-CirpA1 complex and determine its structure to 3.4 Å by X-ray crystallography. The structure was solved by molecular replacement, using models of CirpA1 (this study) and FP Δ 2,3 (pdb-id: 6S08) as search models. In the crystal lattice each FP Δ 2,3 molecule interacts with two inhibitor molecules (fig 3c). Knowing from our SEC-MALS analysis that each FP Δ 2,3 binds only one CirpA1 in solution, we designed two CirpA1 mutants, introducing arginine residues at distinct positions in each interface (E170R/V173R and Q148R) which based on our structure would likely disrupt the corresponding interaction with FP. Using an alternative pathway haemolysis assay, we were able to show that CirpA1 E170RV173R displays similar properties as the wild-type. In contrast, the CirpA1 inhibitory effect is lost in the Q148R mutant indicating that interface 2 is the functionally relevant one. CirpA1 binds properdin at TSR5 and 6, in immediate proximity to the convertase binding region (fig 3e). We observe clear density for the majority of large side chains resulting in high confidence in our fitted model (fig 3f).

Figure 3 Analysis of the CirpA1 binding behaviour to human properdin. (a) Size exclusion chromatography of properdin isolated from human serum with and without pre-bound CirpA1. (b) SEC-MALS demonstrates binding of CirpA1 to FPΔ2,3 in a 1:1 stoichiometry. (c) Crystal contacts observed between CirpA1 and FPΔ2,3 result in two possible binding sites of CirpA1. (d) AP haemolysis assay with serum from *Homo sapiens* (human), WT= wild-type CirpA1, E170RV173R = CirpA1 carrying point mutation in crystal contact 1, Q148R = CirpA1 carrying point mutation in crystal contact 2. (e) Crystal structure of the complex between FPΔ2,3 (blue) and CirpA1 (rainbow) (f) Close up of the 2Fo-Fc, α c map in the FPΔ2,3-CirpA1 interface region (left) and the CirpA1 C-terminal helix.

Analysis of the interaction surface, which is burying 864 Å², reveals complementary charged patches, suggesting that binding is mediated by electrostatic interactions (Fig 4a). Superposition with structures of isolated FPΔ2,3 as well as FPΔ2,3 in complex with the C-terminal domain of C3b shows subtle conformational changes in the binding region (Fig. 4b). In CirpA1, FP binding leads to structural changes in the three C-terminal beta strands, as well as specific rearrangements of individual amino acids contributing to complex stability (Fig 4c, Suppl. Fig 2). One example is Q148 which forms a hydrogen bond to FP Q338 (Fig 3f and Fig 4c). Superposition with structures of the CirpA3-5 shows that CirpA3 and CirpA4 could rearrange analogously to form this interaction, while in CirpA5 Q148 is replaced with a glycine residue (Fig 4d). Interestingly, sequence comparison of FP between the species tested for CirpA activity shows that Q/E at position 338 is unique to primates. Our structure suggests that substitution with aspartate (rat) or lysine (guinea pig) would likely weaken the interaction, contributing to CirpA1 activity loss in these species (Fig 4e).

Another CirpA1 residue undergoing a conformational rearrangement upon FP binding is Y122 which forms a hydrophobic pocket around properdin P377 together with CirpA1 residues F122, Y131 and F150. This pocket is incomplete in all three CirpA1 homolog structures.

Together with the fact that the CirpA1 regions forming the FP binding interface overlap with the regions of highest conformational variability between the CirpA homolog structures (Fig 4f), these changes might provide an explanation for lack of human FP-inhibition activity of CirpA3-A5 in our analysis.

Figure 4 Detailed analysis of the CirpA1- properdin interaction. (a) Positive (blue) and negative (red) electrostatic potential regions mapped onto the surface representations of CirpA1 and FPΔ2,3 from the FPΔ2,3-CirpA1 complex. Interface region area highlighted by dotted lines. (b) Overlay of structural models of isolated FPΔ2,3 (PDB 6S08, light grey), FPΔ2,3-C3-c345c (PDB 6S0B, dark grey) and FPΔ2,3-CirpA1 (PDB 7B26, blue/magenta) aligned to properdin residues 320-440. Close up of CirpA1 interfacing region. (c) Structural changes in CirpA1 upon complex formation with FPΔ2,3 (d) Superposition of structural models of CirpA3-5 (shades of grey) with the CirpA1- FPΔ2,3 complex, view as in (c). (e) Multiple sequence alignment of properdin from species used in AP haemolysis assays in Figure 2b, showing the regions interacting with CirpA1, red: residues unique to species inhibited by CirpA1, black dots: residues involved in the CirpA1- FPΔ2,3 interface in the complex structure in fig. 3e according to PISA analysis. (f) Close up view of the CirpA1- FPΔ2,3 interface, regions of high conformational variability between CirpA homologs as identified in fig. 2d highlighted with dashed lines.

In a broader context of complement activation, CirpA1 is not the first known tick lipocalin mediating potent inhibition. The complement inhibitor OmCI binds the C5 in close vicinity to its C345C domain and prevents cleavage of C5 by the C5 complement convertases, thereby preventing release of anaphylatoxin C5a and formation of the terminal membrane attack complex (MAC) (Fig 5a). In contrast, CirpA1 acts at an upstream step, by binding to FP and interfering with assembly and stabilisation of the C3 convertase. Remarkably, despite their high structural similarity, OmCI and CirpA1 bind their targets in very different regions of the lipocalin surface (Fig 5b-d). In addition, OmCI displays a second mechanism of function by binding the

proinflammatory eicosanoid leukotriene B4 (LTB₄) within an internal binding cavity. The corresponding pocket in CirpA1 is blocked by a cluster of charged residues, precluding binding of a hydrophobic ligand in this position (Fig 5 e,f).

Figure 5 Broader context of CirpA1-mediated complement inhibition. (a) Schematic representation of the complement cascade indicating the point of inhibition of CirpA1 (dark red) in comparison to OmCI (light green) (b) Overlay of structural models of CirpA1 (dark red) and OmCI (grey) (c) Side and top views of the CirpA1 structure, regions on the CirpA1 surface representation involved in FP Δ 2,3 binding are highlighted in red. (d) Side and top views of the OmCI structure, regions on the OmCI surface representation involved in C5 binding are highlighted in green. (e) Close-up of the OmCI ligand binding pocket, bound to leukotriene B4 (PDB 3zu0). (f) CirpA1 region corresponding to the OmCI pocket shown in (e). (g) Cartoon representation the proposed mechanism of CirpA1-mediated complement inhibition via blocking of properdin binding (center) or displacing pre-bound properdin (right) in contrast to undisturbed convertase binding in absence of CirpA1 (left).

Discussion

We have identified a novel complement inhibitor from the hard tick *R. pulchellus*. Our functional and structural analyses show that it targets FP, the only known positive regulator of the human complement system. Sequence analyses identified five additional members of the CirpA family, with pairwise sequence identities to CirpA1 between 43-82%. Their anti-complement activity does not seem to correlate with the degree of sequence conservation and is specific to serum of certain species. To understand the differences in inhibition profile, we determined the structures of CirpA1, CirpA3, CirpA4, CirpA5 and CirpA1-FP Δ 2,3. The structures revealed a lipocalin-like fold for all CirpA homologs. We identified three regions with high conformational variability between homologs. All these regions are part of the binding interface between CirpA1 and FP, and hence the conformational differences might render other homologs incompatible with FP binding.

The natural hosts of the three tick species producing the characterised CirpA homologs are mostly cattle and other larger domestic animals. In light of that, it seems likely that the proteins have evolved to target other species, which were not tested in this study. Lipocalins are known to be functionally diverse^{29, 30}. In addition to binding small, often hydrophobic molecules in designated pockets in their beta-barrel, some have additional functionality by engaging in protein-protein interactions. Therefore, the lack of inhibition of AP mediated haemolysis observed for CirpA2-5 might also be due to the fact that their activity lies within a different aspect of the complement cascade, or even in another biological pathway.

The functional versatility of lipocalin tick inhibitors is further illustrated by our comparison of CirpA1 and OmCI. OmCI binds leukotriene B4 and forms a complex with complement C5, thereby inhibiting the terminal steps of the complement response. Evaluating the structures of these inhibitors in isolation and in complex with FP or C5 shows that both their internal pocket as well as their protein binding regions are very distinct from each other. Nevertheless, both lipocalins cause a potent block for the corresponding complement pathways.

The CirpA1- FP Δ 2,3 structure also sheds light on how CirpA1 interferes with properdin function. High resolution structures of isolated FP Δ 2,3 and the C3b-c345c-FP Δ 2,3 complex, together with a moderate resolution structure of convertase-bound pseudo monomeric FP, have established that FP interacts with the convertase mainly through contacts with the C-terminal C345c domain of C3b^{18, 19, 20}. It binds the convertase via TSR5 and TSR6 near the factor B binding site. It is plausible that binding is strengthened through direct contacts between FP and Bb, but resolution limitations did not allow to unambiguously pinpoint interacting residues. Two distinct loops in FP were shown to play a crucial role in binding to C3b: residues 328-333 (336 in¹⁸) (TSR5-stirrup or thumb) and residues 419-426 (TSR6-stirrup or index finger). They embrace the C-terminal helix of C3b and might be involved in stabilising the Mg²⁺ coordination between C3b and Bb.

In context of the properdin bound C3 convertase, binding of CirpA1 results in a steric clash between CirpA1 and the protease component Bb. This direct competition might contribute to the CirpA1 inhibitory effect *in vivo*. However, it cannot be the only component explaining CirpA1-mediated inhibition as our work shows that CirpA1 prevents FP binding to C3b in the absence of FB, and promotes dissociation of a preformed C3b-FP complex. Therefore, the CirpA1 inhibitory mechanism is likely to interfere directly with the FP-C3b interaction. Notably, the TSR5-stirrup is directly involved in CirpA1 binding. The TSR6-stirrup lies in immediate vicinity to another the CirpA interacting region and appears to be disordered in the CirpA1-FP Δ 2,3 structure. While it is similarly flexible in isolated FP Δ 2,3 it assumes a stable conformation upon C3b binding. We therefore rationalise that binding of CirpA1 impacts the conformational freedom of the stirrup loops thereby destabilising the interaction with C3b and possibly preventing conformational changes required for binding to the convertase.

Combining together the results from our structural and functional analyses, we are proposing a model for CirpA1-mediated complement inhibition that mimics the decay acceleration models of convertase regulation (Fig. 5g). In the absence of the inhibitor, the C3 convertase is bound and stabilised by multimeric FP. In presence of CirpA, the inhibitor binds free FP at the TSR5/6 junction, thereby blocking FP from binding the C3 convertase. Furthermore, CirpA1 is capable of binding to convertase-engaged FP molecules, triggering FP displacement.

In summary, our study represents the first all-inclusive characterisation of a human properdin inhibitor covering isolation from its natural source, target identification, functional as well as structural characterisation. In addition, our structure of inhibitor-bound properdin sheds light on the mechanisms involved in properdin-convertase binding, thereby marking an important contribution to understanding the human complement response.

Methods

Fractionation of *R. pulchellus* Salivary Glands

R. pulchellus ticks were reared, and 250 salivary glands from 6-day fed female *R. pulchellus* were dissected according to Tan et al.²⁷. The gland protein extract was topped up with 25 mM Na₂HPO₄/NaH₂PO₄, pH 7.0 to 10 mL. The sample was then fractionated by sequential anion exchange, hydrophobic interaction chromatography and size exclusion chromatography

(SEC). At each stage, eluted fractions and flow-through from the chromatographic columns were assayed for complement inhibitory activity, and the active fractions were further fractionated. First, protein extract was fractionated by anion exchange chromatography using a MonoQ 5/50 GL column (GE Healthcare), washed with 10 column volumes (CV) 25 mM Na₂HPO₄/NaH₂PO₄, pH 7.0, and eluted by a 0 to 0.5 M NaCl gradient over 30 CV in 500-μL fractions. Active fractions were combined, mixed with an equal volume of 3.4 M (NH₄)₂SO₄, pH 7.0, centrifuged (22,000 x g, 10 min), and the supernatant topped up to 5 mL with 1.7 M (NH₄)₂SO₄, 100 mM Na₂HPO₄/NaH₂PO₄, pH 7.0. The sample was loaded onto a 1-mL HiTrap Butyl HP column (GE Healthcare) and washed with 5 CV of 1.7 M (NH₄)₂SO₄, 100 mM Na₂HPO₄/NaH₂PO₄, pH 7.0. Elution was carried out by a 1.7 to 0.0 M (NH₄)₂SO₄ gradient over 15 CV in 1-mL fractions. The active fraction was topped up to 220 μL with PBS, separated by a Superdex S75 10/300 column (GE), and collected in 250 μL fractions. All fractions were buffer exchanged to PBS and concentrated.

Identification of CirpA1

Identified protein fractions with complement-inhibitory abilities were digested by Trypsin and analyzed by LC-MS/MS. Samples were topped up to 50 μL with 50 mM TEAB, pH 8.5, reduced with 20 mM TCEP (21 °C, 30 min), alkylated with 50 mM chloroacetamide in the dark (21 °C, 30 min), digested with 0.5 μg of trypsin (37 °C, 16 h), then quenched with 1 μL formic acid. Digested peptides were analyzed by LC-MS/MS over a 30-min gradient using LTQ XL-Orbitrap (Thermo Scientific) at the CentralProteomicsFacility (<http://www.proteomics.ox.ac.uk>, Sir William Dunn School of Pathology, Oxford, United Kingdom). Data were analyzed using the central proteomics facilities pipeline³¹ and peptides were identified by searching against two *R. pulchellus* sialome cDNA databases^{26, 27} with Mascot (Matrix Science). Hits were assessed for the presence of a signal peptide with the SignalP 4.1 Server³² (Copenhagen Business School, Technical University of Denmark), sequence homology to known protein sequences by blastp (NCBI), and structural homology to known protein structures by FFAS³³.

Expression and Purification of Recombinant Proteins.

Insect Cell expression

Codon-optimized GeneArt strings were cloned into pExpreS2-2 vector with the insect BiP signal sequence followed by an N-terminal 6-His tag. Transfections into *Drosophila melanogaster* S2 suspension cells were carried out following the manufacturer's instructions (Expres2ion Biotechnologies).

E.coli expression

CirpA1 was codon-optimised, cloned into pETM-14 using the NcoI and NotI restriction enzymes and transformed into *E. coli* BL21 (DE3) (New England Biolabs). CirpA3, CirpA4 and CirpA5 were codon optimised, cloned into pET15b vector using the restriction enzymes NcoI and XhoI and transformed into *E. coli* BL21 (DE3) (New England Biolabs). Protein expression was carried out in LB broth (with 50 μg/mL kanamycin). Cells were induced with 1 mM isopropyl- β-D-thiogalactopyranoside (IPTG) for 16h at 20 °C, resulting in expression in inclusion bodies.

Purification of Tick Inhibitors from insect cells

The supernatant was harvested and filtered. Expressed proteins were subsequently purified using a cOmplete His-Tag Purification column (1mL column, Roche) and SEC (S200, 16/60, GE Healthcare) in PBS.

Purification of Tick Inhibitors from *E.coli*

Cells were harvested by centrifugation and lysed by homogenisation. The lysate was spun at 20,000 rpm, 4 C for 30 min and the cell pellet fraction was re-suspended in 40 ml of Buffer A (50 mM Tris, 150 mM NaCl, pH 8, 0.05% (v/v) Tween 20) using a hand-held homogeniser. After incubation on a rotary wheel at 4 oC for 1 h, the re-suspended pellet was centrifuged at 20,000 rpm at 4 C for 30 min. This wash step was repeated once more. The cell pellet was then resuspended in 40 ml of Buffer B (8 M urea, 1 mM EDTA, 100 mM Tris, 25 mM DTT, pH 8) for solubilisation of inclusion bodies, and incubated on a rotary wheel at 4 C for 2 h. Following centrifugation, the supernatant fraction was retained and filtered. For refolding, the supernatant was added dropwise to Buffer C (1 mM cysteine, 2 mM cystine, 20 mM ethanolamine, 1 mM EDTA, pH 11) with stirring. The protein-containing refolding buffer was left overnight at 4 C, and then concentrated down to ~40 ml using a 10 kDa Vivaflow 200 filtration device (Sartorius). For CirpA1, the His-Tag was removed following concentration via cleavage with 3C protease whilst dialysing against 2 l of Buffer D (50 mM Tris, 150 mM NaCl, pH 8) overnight at 4 C. Uncleaved material was removed by reverse nickel purification. All inhibitors were purified by SEC (S75, 26/60, GE Healthcare) in Buffer D. CirpA3, CirpA4 and CirpA5 were further purified by ion exchange chromatography (Mono Q 5/50 column, GE Healthcare). Homogeneous protein populations eluted in the peak (CirpA3, CirpA4) and flow-through (CirpA5) fractions and were dialysed against 50 mM Tris, 20 mM NaCl, pH 8.5, overnight at 4 C.

Purification of human Properdin from serum

An affinity column was generated with CirpA1 using the Pierce NHS-Activated Agarose Slurry (Thermo Scientific) following the manufacturer's instructions. In brief, CirpA1 was mixed with the slurry on a rotary wheel overnight at 4 C. After coupling, the remaining active sites were blocked with 1 M ethanolamine. The slurry was then packed into an empty cartridge to generate a CirpA1 'column'. Normal human serum was acquired from the John Radcliffe Hospital, Oxford. After loading the serum onto the CirpA1 column and washing with PBS, properdin was eluted with 0.2 M glycine-HCl, pH 3. The pH of the elution fraction was adjusted by adding 50 µl of neutralisation buffer (1 M Tris, pH 9) per 1 ml of eluate. Elution fractions were further purified by SEC (S200 10/30 GE Healthcare) in PBS, pH 7.4. The presence of properdin in the elution fraction was confirmed by SDS-PAGE and Western blot.

Expression and Purification of human monomeric Properdin lacking TSR 2, 3

HEK293F cell expression

Monomeric properdin lacking TSR domains 2 and 3 was prepared as previously described¹⁸.

Purification of CirpA1-FP complex

Purified FPCdel2,3 was mixed with refolded CirpA1 at a 1:1.5 ratio and incubated for 5 min at RT. The complex was separated from excess CirpA1 by SEC (S200 16/60 GE Healthcare) in 20 mM Tris/HCl pH 7.5, 100 mM NaCl. A 1:1 stoichiometry was confirmed using SEC-MALS (S200, 10/300 GL GE Healthcare).

Complement Inhibition Assays

Complement inhibition ELISAs were performed using a Wieslab complement system screen (Euro Diagnostica) following the manufacturer's instructions, with sample added prior to serum. Assays for the classical and lectin pathways were performed with sheep red blood cells (TCS Biosciences) sensitized with anti-sheep red blood cell stroma antibody (cat. no. S1389, Sigma-Aldrich), alternative pathway assay was performed with rabbit red blood cells (TCS Biosciences). Human serum dilution of 1:18, 1:101 and 1:101 were used for the AP, CP and LP, respectively. Alternative pathway haemolysis inhibition assays were carried out with rabbit red blood cells (TCS Biosciences) as described previously²⁸. Serial dilutions of tick inhibitors purified from insect cells were used to assay interspecies activity whereas wt and mutant

CirpA1 purified from *E. coli* was used to distinguish Properdin binding sites. Briefly, fifty microliters of cells (2×10^8 cells/mL) were incubated in an equal volume of diluted serum (1 h, 37 °C, shaking), supplemented with 2 µL of purified inhibitor or control. Cells were pelleted and haemolysis was quantified at 405 nm of supernatant. Cells with serum only were used for normalization (100% activity). Final serum dilutions used were as follows: 1:5 (human), 1:6 (monkey), 1:3 (rat) and 1:5 (guinea pig). Human serum from healthy volunteers was prepared as previously described²⁸; *Macaca fascicularis* serum was a kind gift from John Davis and Elena di Daniel; rat and guinea pig serum were from Complement Technology.

Pull-Down Assay

For pull-down assay, 0.1 mg/mL of purified protein was immobilized on Pierce NHS-activated magnetic beads (Thermo Fisher) following the manufacturers' instructions. The beads were incubated with 10 mM EDTA and 50 µL serum (21 °C, 30 min). The beads were washed 3 times with 1 mL PBS + 0.05% Tween20, once with 100 µL PBS, and boiled in 50 µL SDS-PAGE loading buffer. Elutions were analysed by SDS-PAGE and semi-dry Western blotting.

Competition Assay

Biotinylated C3b (bC3b) was prepared as previously described⁴. 0.1 mg/mL bC3b in PBS was immobilised on MagStrep "type3" XT Beads (Iba) using 250 µL resin per mL. To prevent complement activation and thereby uncouple the effects of properdin binding to C3b vs. Properdin binding to fully assembled convertases, human serum was pre-treated with 10 mM EDTA and 10 mM EGTA. Pre-inhibited serum was prepared by adding 10 µM CirpA1 to the inactivated serum and incubating 30 min at 25°C. To investigate Properdin binding to C3b in the presence or absence of CirpA1 25 µL bC3b bound beads were incubated for 2.5 h at 25 °C in 100 µL of inactivated serum or 100 µL pre-inhibited serum. 25 µL beads without bC3b were incubated with inactivated serum as a negative control. The beads were washed 5 times with 100 µL PBS. To study competitive binding of CirpA1, 25 µL of beads that had not previously contained CirpA1 were subsequently incubated for 30 min with 100 µL 10 µM CirpA1 in PBS at 25°C. The FT was collected, and the beads were washed 5 times with 100 µL PBS. Beads from all reactions were resuspended in twice the bead volume of SDS sample buffer and heated to 95 °C for 10 min to elute all bound protein immediately after the last wash. The elutions from all reactions as well as the flow-through from the competition sample were analysed by SDS-PAGE followed by semi-dry Western Blotting against Properdin.

Semi-dry Western blotting

For blotting the SDS/PAGE-separated proteins were transferred to a PVDF membrane (Amersham Hybond P0.2 PVDF, 55 GE) by semiwet transfer (Bio-Rad) and blocked for 1 h with PBS/2% milk.

Primary antibody (goat α-FP: 1:2,000, Complement Technology). Secondary antibody (donkey α-goat HRP, Promega, 1:10,000). For His-tagged proteins, the Penta-His HRP Conjugate Kit (Qiagen) was used following manufacturer's instructions.

Blots were developed using ECL Western Blotting Substrate (Promega) and imaged using Amersham Hyperfilm ECL (GE Healthcare) or using a ChemiDoc XRS+ imaging system (Biorad).

SEC-MALS

For SEC-MALS, 100 µL of protein sample at 1 mg/mL was injected onto an S200 10/300 column (GE Healthcare) equilibrated in PBS. Light scattering and refractive index were measured using a Dawn Heleos-II light scattering detector and an Optilab-TrEX refractive

index monitor. Analysis was carried out using ASTRA 6.1.1.17 software assuming a dn/dc value of 0.186 mL/g.

Crystallization, X-Ray Data Collection, and Structure Determination

Refolded CirpA1 in 50 mM Tris, 150 mM NaCl, pH 8 was concentrated to 17.8 mg/mL. The protein was mixed with an equal volume of mother liquor containing 0.2 M imidazole malate, pH 6, 30% (w/v) PEG4000, and crystallized in 300-nL drops by a vapor-diffusion method at 21 °C. Crystals were cryoprotected in mother liquor supplemented with 20% (v/v) PEG400 and flash-frozen in liquid N₂. Data were collected on beamline I04 at the Diamond Light Source (Harwell, United Kingdom), wavelength: 0.9795 Å, as specified in Table 1. The structure of CirpA1 was solved by molecular replacement using MolRep³⁴ within CCP4³⁵. The search model was created using Chainsaw in CCP4³⁶ based on the structure of OmCI (PDB ID code 3ZUI). The initial model of CirpA1 was built and refined through iterations of Buccaneer³⁷ and REFMAC5³⁸. Subsequently, the model was subjected to multiple rounds of manual rebuilding in Coot³⁹ and refinement in REFMAC5³⁸ or Phenix⁴⁰.

Initial crystallisation trays were set up with full length refolded CirpA3. Crystal quality could be substantially improved by using a truncated CirpA3 construct (encompassing residues 6-160). Refolded, truncated CirpA3 (6-160) in 50 mM Tris, 150 mM NaCl, pH 8 was concentrated to 13.1 mg/mL. The protein was mixed in a 1:3 ratio with mother liquor containing 0.2 M ammonium sulphate, 30% (w/v) PEG 4000, and crystallized in 300-nL drops by a vapor-diffusion method at 21 °C. Crystals were cryoprotected in mother liquor supplemented with 20% (v/v) PEG400 and flash-frozen in liquid N₂. Data were collected on beamline I04-1 at the Diamond Light Source (Harwell, United Kingdom), wavelength: 0.9762 Å, as specified in Table 1. The structure of CirpA3 was solved by molecular replacement using MolRep³⁴ within CCP4³⁵. The search model was created using Chainsaw in CCP4³⁶ based on the structure of CirpA1. Subsequently, the model was subjected to multiple rounds of manual rebuilding in Coot³⁹ and refinement in Phenix⁴⁰. The presence of twinning was identified by Xtriage⁴¹ based on the intensity statistics. Therefore, the final stages of refinement in PHENIX were performed using the twin law (l,-k,h) as obtained from Xtriage.

Refolded CirpA4 in 50 mM Tris, 150 mM NaCl, pH 8 was concentrated to 9.6 mg/mL. The protein was mixed in a 1:3 ratio with mother liquor containing 0.005 M cadmium chloride hemi(pentahydrate), 0.1 M sodium acetate, pH 5.5, 20% (w/v) PEG 4000, and crystallized in 300-nL drops by a vapor-diffusion method at 21 °C. Crystals were cryoprotected in mother liquor supplemented with 20% (v/v) PEG400 and flash-frozen in liquid N₂. Data were collected at the MASSIF1 beamline of ESRF by automatic data collection, using an X-ray beam of wavelength 0.966 Å, as specified in Table 1. The structure of CirpA4 was solved by molecular replacement using MolRep³⁴ within CCP4³⁵ with the structure of CirpA1. Subsequently, the model was subjected to multiple rounds of manual rebuilding in Coot³⁹ and refinement in Phenix⁴⁰.

Refolded CirpA5 in 50 mM Tris, 150 mM NaCl, pH 8 was concentrated to 21.5 mg/mL. The protein was mixed in a 1:3 ratio with mother liquor containing 0.1 M Sodium HEPES, pH 8.2, 50% (v/v) PEG500 MME, and crystallized in 300-nL drops by a vapor-diffusion method at 21 °C. Crystals were cryoprotected in mother liquor and flash-frozen in liquid N₂. Data were collected on beamline I04-1 at the Diamond Light Source (Harwell, United Kingdom), wavelength: 0.9159 Å, as specified in Table 1. The structure of CirpA5 was solved by molecular replacement using MolRep³⁴ within CCP4³⁵ using the structure of CirpA1 as a search model. The structure of Cirp-A5 was built and refined through cycles of automated model building by Buccaneer³⁷ and refinement by REFMAC5³⁸. Subsequently, the model was subjected to multiple rounds of manual rebuilding in Coot³⁹ and refinement in REFMAC5³⁸ or Phenix⁴⁰.

CirpA1 was copurified with the FPdel2,3 by SEC (S200 16/60 GE Healthcare) in 20 mM Tris/HCl pH 7.5, 100 mM NaCl and concentrated to 10.5 mg/mL. The protein was mixed with an equal volume of mother liquor containing 0.15 M Potassium thiocyanate, 0.1 M Tris, pH 7.5, 18 % w/v PEG 5000 MME, and crystallized in 200-nL drops by a vapor-diffusion method at 21 °C. Crystals were cryoprotected in mother liquor supplemented with 20% (v/v) PEG400 and flash-frozen in liquid N₂. Data were collected on beamline I04-1 at the Diamond Light Source (Harwell, United Kingdom), wavelength: 0.915890 Å, as specified in Table 1. The structure of the complex was solved by molecular replacement using MolRep³⁴ within CCP4 with the structures of CirpA1 (PDB ID code 7BD2, this study) and FPcdel2,3 (PDB ID code 6S08). The initial model was subjected to multiple rounds of manual rebuilding in Coot³⁹ and refinement in Phenix⁴⁰. The protein chemistry of the final models was validated using MolProbity⁴². The structures are characterized by the statistics shown in Table 1. Interactions between CirpA1 and FP have been predicted by PDBePISA⁴³. Protein structure figures were prepared using Pymol v2.4 (Schrödinger). Electrostatic potentials were calculated using the APBS program in Pymol⁴⁴.

Acknowledgements

We acknowledge the Diamond Light Source and the staff of beamlines I04 and I04-1 for access under proposals mx12346 and mx18069. We further acknowledge the European Synchrotron Radiation Facility and the staff of beamline MASSIF1. We thank M. Slovak (Institute of Zoology, Bratislava, Slovakia) for providing salivary glands; John Davis and Elena di Daniel (Oxford Drug Discovery Institute) for providing *Macaca fascicularis* serum; Simon Newstead (Biochemistry, Oxford) for assistance with Synchrotron data collection

This work was financially supported by the European Molecular Biology Organisation long-term postdoctoral fellowship ALTF 554-2019 to K.B.; Wellcome Trust grants 100298, 209194, and 219477 to S.M.L.; and Medical Research Council UK grant S021264 to S.M.L.

Author contributions

S.J., M.M.J., K.B., J.A., G.R.A. and S.M.L. designed research; K.B., J.A., M.M.J., S.J., T.T., D.V.P., and S.M.L. performed research; K.B. J.A., S.J., M.M.J., and S.M.L. analysed data; and K.B., S.J., and S.M.L. wrote the paper.

Competing interest statement: M.M.J. and S.M.L. are authors on a patent application that describes members of the inhibitor family as potential protein therapeutics.

Data deposition

X-ray coordinates and data have been deposited into the Protein Data Bank (PDB), www.pdb.org under accession codes PDB 7B2D (CirpA1), PDB 7B28 (CirpA3), PDB 7B29 (CirpA4), PDB 7B2A (CirpA5), PDB 7B26 (CirpA1-FPΔTSR2,3). CirpA inhibitor sequences have been deposited into the GenBank under accession codes MW260265 (CirpA1), MW260267 (CirpA2) and MW260266 (CirpA3); or have already been publicly available under accession codes CD794868 (CirpA4), GEFJ01011401 (CirpA5) and CK182034 (CirpA6).

Table 1 Data collection and refinement statistics (molecular replacement)

	CIRpA1	CIRpA3	CIRpA4	CIRpA5	CIRpA1- FPΔ2,3
Data collection					
Space group	P222 ₁	P2 ₁	P2 ₁ 2 ₁ 2 ₁	I222	P2 ₁ 2 ₁ 2
Cell dimensions a, b, c (Å)	72.60, 45.85, 57.48	68.366, 150.298, 68.430	40.12, 54.33, 79.73	52.01, 71.32, 110.15	166.31, 54.51, 70.58
α, β, γ (°)	90.0, 90.0, 90.0	90.0, 91.83, 90.0	90.0, 90.0, 90.0	90.0, 90.0, 90.0	90.0, 90.0, 90.0
Resolution (Å)	45.06-1.96 (2.01-1.96) *	62.25-1.92 (2.11-1.92)	44.90-1.83 (1.86-1.83)	55.08-1.91 (1.96-1.91)	83.16-2.84 (3.28-2.84)
R _{sym} or R _{merge}	12.2 (131.7)	12.0 (67.4)	7.0 (47.9)	24.7 (180.0)	35.7 (182.0)
I / σI	11.5 (1.4)	6.3 (1.5)	11.0 (2.1)	5.3 (1.0)	6.1 (1.7)
Completeness (%)	100.0 (100.0)	92.2 (61.4)	93.2 (100.0)	99.9 (99.9)	89.4 (62.5)
Redundancy	11.4 (7.1)	3.3 (3.2)	4.0 (3.7)	6.4 (6.9)	10.7 (9.7)
CC _{1/2} (%)	99.8 (57.1)	99.3 (51.5)	99.7 (77.7)	98.8 (58.0)	99.4 (59.9)
Refinement					
Resolution (Å)	45.07-1.96 (2.11-1.96)	62.25-2.10 (2.14-2.10)	44.90-1.83 (1.97-1.83)	55.08-1.91 (2.03-1.91)	24.71-3.40 (4.28-3.40)
No. reflections	14297	60529	14798	16258	6822
R _{work} / R _{free}	19.27/21.92	21.70/25.04	19.15/23.60	21.95/24.37	22.92/27.41
No. atoms					
Protein	1273	9935	1305	1340	3684
Ligand/ion	18	5	4	15	120
Water	116	711	161	167	-
B-factors					
Protein	39.04	34.23	28.83	31.12	65.21
Ligand/ion	70.40	37.77	62.95	78.67	62.65
Water	40.53	28.71	36.42	7.36	-
R.m.s. deviations					
Bond lengths (Å)	0.008	0.003	0.004	0.002	0.004
Bond angles (°)	0.887	0.531	0.706	0.534	0.874

*Values in parentheses are for highest-resolution shell.

References

1. Bennett, K.M., Rooijackers, S.H.M. & Gorham, R.D. Let's tie the knot: Marriage of complement and adaptive immunity in pathogen evasion, for better or worse. *Frontiers in Microbiology* **8**, 1-17 (2017).
- 5 2. Merle, N.S., Church, S.E., Fremeaux-Bacchi, V. & Roumenina, L.T. Complement system part I - molecular mechanisms of activation and regulation. *Frontiers in Immunology* **6**, 1-30 (2015).
- 10 3. Ricklin, D., Hajishengallis, G., Yang, K. & Lambris, J.D. Complement: A key system for immune surveillance and homeostasis. *Nature Immunology* **11**, 785-797 (2010).
4. Berends, E.T.M. *et al.* Molecular insights into the surface-specific arrangement of complement C5 convertase enzymes. *BMC Biology* **13**, 1-13 (2015).
- 15 5. Merle, N.S., Noe, R., Halbwachs-Mecarelli, L., Fremeaux-Bacchi, V. & Roumenina, L.T. Complement system part II: Role in immunity. *Frontiers in Immunology* **6**, 1-26 (2015).
6. Ricklin, D., Mastellos, D.C., Reis, E.S. & Lambris, J.D. The renaissance of complement therapeutics. *Nature Reviews Nephrology* **14**, 26-47 (2018).
- 20 7. Holter, J.C. *et al.* Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. *Proceedings of the National Academy of Sciences of the United States of America* **117**, 25018-25025 (2020).
- 25 8. Java, A. *et al.* The complement system in COVID-19: friend and foe? *JCI insight* **5** (2020).
9. Risitano, A.M. *et al.* Complement as a target in COVID-19? *Nature Reviews Immunology* **20**, 343-344 (2020).
- 30 10. Skendros, P. *et al.* Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. *Journal of Clinical Investigation* (2020).
11. Chen, J.Y., Cortes, C. & Ferreira, V.P. Properdin: A multifaceted molecule involved in inflammation and diseases. *Molecular Immunology* **102**, 58-72 (2018).
- 35 12. Fearon, D.T. & Austen, K.F. Properdin: Binding to C3b and Stabilization of the C3b-dependent C3 convertase. *The Journal of Experimental Medicine* **142**, 856-863 (1975).
- 40 13. Pillemer, L. *et al.* The properdin system and immunity: I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. *Science* **120**, 279-285 (1954).

14. Medicus, R.G., Schreiber, R.D., Gotze, O. & Mueller Eberhard, H.J. A molecular concept of the properdin pathway. *Proceedings of the National Academy of Sciences of the United States of America* **73**, 612-616 (1976).
- 5 15. Schreiber, R.D., Medicus, R.G., Goetze, O. & Mueller Eberhard, H.J. Properdin and nephritic factor dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor. *Journal of Experimental Medicine* **142**, 760-772 (1975).
- 10 16. Harrison, R.A. The properdin pathway: an “alternative activation pathway” or a “critical amplification loop” for C3 and C5 activation? *Seminars in Immunopathology* **40**, 15-35 (2018).
17. Kemper, C., Atkinson, J.P. & Hourcade, D.E. Properdin: Emerging Roles of a Pattern-Recognition Molecule. *Annual Review of Immunology* **28**, 131-155 (2010).
- 15 18. Pedersen, D.V. *et al.* Structural Basis for Properdin Oligomerization and Convertase Stimulation in the Human Complement System. *Frontiers in Immunology* **10** (2019).
19. Pedersen, D.V. *et al.* Functional and structural insight into properdin control of complement alternative pathway amplification. *The EMBO Journal* **36**, 1084-1099 (2017).
- 20 20. van den Bos, R.M., Pearce, N.M., Granneman, J., Brondijk, T.H.C. & Gros, P. Insights Into Enhanced Complement Activation by Structures of Properdin and Its Complex With the C-Terminal Domain of C3b. *Frontiers in Immunology* **10**, 1-19 (2019).
- 25 21. Michels, M.A.H.M. *et al.* Novel assays to distinguish between properdin-dependent and properdin-independent C3 nephritic factors provide insight into properdin-inhibiting therapy. *Frontiers in Immunology* **10**, 1-16 (2019).
- 30 22. Chmelar, J., Kotál, J., Kováříková, A. & Kotsyfakis, M. The use of tick salivary proteins as novel therapeutics. *Frontiers in Physiology* **10**, 1-10 (2019).
23. Nunn, M.A. *et al.* Complement Inhibitor of C5 Activation from the Soft Tick *Ornithodoros moubata*. *The Journal of Immunology* **174**, 2084-2091 (2005).
- 35 24. Roversi, P. *et al.* The Structure of OMCI, a Novel Lipocalin Inhibitor of the Complement System. *Journal of Molecular Biology* **369**, 784-793 (2007).
25. Roversi, P. *et al.* Bifunctional lipocalin ameliorates murine immune complex-induced acute lung injury. *Journal of Biological Chemistry* **288**, 18789-18802 (2013).
- 40 26. Reichhardt, M.P. *et al.* An inhibitor of complement C5 provides structural insights into activation. *Proceedings of the National Academy of Sciences of the United States of America* **117**, 362-370 (2020).

27. Tan, A.W.L., Francischetti, I.M.B., Slovak, M., Kini, R.M. & Ribeiro, J.M.C. Sexual differences in the sialomes of the zebra tick, *Rhipicephalus pulchellus*. *Journal of Proteomics* **117**, 120-144 (2015).
- 5 28. Jore, M.M. *et al.* Structural basis for therapeutic inhibition of complement C5. *Nature Structural and Molecular Biology* **23**, 378-386 (2016).
29. Flower, D.R. The lipocalin protein family: Structure and function. *Biochemical Journal* **318**, 1-14 (1996).
- 10 30. Valdés, J.J. *et al.* Substrate prediction of *Ixodes ricinus* salivary lipocalins differentially expressed during *Borrelia afzelii* infection. *Scientific Reports* **6**, 1-14 (2016).
- 15 31. Trudgian, D.C. *et al.* CPFP: A central proteomics facilities pipeline. *Bioinformatics* **26**, 1131-1132 (2010).
32. Petersen, T.N., Brunak, S., Von Heijne, G. & Nielsen, H. SignalP 4.0: Discriminating signal peptides from transmembrane regions. *Nature Methods* **8**, 785-786 (2011).
- 20 33. Jaroszewski, L., Li, Z., Cai, X.H., Weber, C. & Godzik, A. FFAS server: Novel features and applications. *Nucleic Acids Research* **39**, 38-44 (2011).
34. Vagin, A. & Teplyakov, A. Molecular replacement with MOLREP. *Acta Crystallographica Section D: Biological Crystallography* **66**, 22-25 (2010).
- 25 35. Winn, M.D. *et al.* Overview of the CCP4 suite and current developments. *Acta Crystallographica Section D: Biological Crystallography* **67**, 235-242 (2011).
- 30 36. Stein, N. CHAINSAW: A program for mutating pdb files used as templates in molecular replacement. *Journal of Applied Crystallography* **41**, 641-643 (2008).
37. Cowtan, K. The Buccaneer software for automated model building. 1. Tracing protein chains. *Acta Crystallographica Section D: Biological Crystallography* **62**, 1002-1011 (2006).
- 35 38. Murshudov, G.N. *et al.* REFMAC5 for the refinement of macromolecular crystal structures. *Acta Crystallographica Section D: Biological Crystallography* **67**, 355-367 (2011).
39. Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development of Coot. *Acta Crystallographica Section D: Biological Crystallography* **66**, 486-501 (2010).
- 40 40. Liebschner, D. *et al.* Macromolecular structure determination using X-rays, neutrons and electrons: Recent developments in Phenix. *Acta Crystallographica Section D: Structural Biology* **75**, 861-877 (2019).

41. Adams, P.D. *et al.* PHENIX: A comprehensive Python-based system for macromolecular structure solution. *Acta Crystallographica Section D: Biological Crystallography* **66**, 213-221 (2010).
- 5 42. Chen, V.B. *et al.* MolProbity: All-atom structure validation for macromolecular crystallography. *Acta Crystallographica Section D: Biological Crystallography* **66**, 12-21 (2010).
- 10 43. Krissinel, E. & Henrick, K. Inference of Macromolecular Assemblies from Crystalline State. *Journal of Molecular Biology* **372**, 774-797 (2007).
44. Jurrus, E. *et al.* Improvements to the APBS biomolecular solvation software suite. *Protein Science* **27**, 112-128 (2018).

15